Aflatoxin B1 alters the expression of p53 in cytochrome p450-expressing human lung cells

Toxicological Sciences

Volumn 89, Issue 2, 2006, Pages 399-407

  Van Vleet, Terry R ^a,b   Watterson, Todd L ^a   Klein, Patrick J ^a,c   Coulombe Jr , Roger A ^a  

^a UTAH STATE UNIVERSITY   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

BDE 47; Brominated flame retardant; PBDE; Toxicokinetics

Indexed keywords

AFLATOXIN B1; CASPASE 3; COMPLEMENTARY DNA; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 3A4; ISOPROTEIN; PROTEIN MDM2; PROTEIN P53; CARCINOGEN;

ARTICLE; BRONCHUS MUCOSA; CELL LINE; CONTROLLED STUDY; DIET; GENE MUTATION; HUMAN; HUMAN CELL; LIVER TOXICITY; LIVER TUMOR; LUNG CANCER; LUNG CARCINOGENESIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; TUMOR SUPPRESSOR GENE; APOPTOSIS; BIOSYNTHESIS; CYTOLOGY; DOSE RESPONSE; DRUG EFFECT; LUNG; METABOLISM; TIME; WESTERN BLOTTING;

ANIMALIA;

AFLATOXIN B1; APOPTOSIS; BLOTTING, WESTERN; CARCINOGENS, ENVIRONMENTAL; CELL LINE; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LUNG; TIME FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 31144451094     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfj039     Document Type: Article

References (72)

1. Agopyan, N., Bhatti, T., Yu, S., and Simon, S. A. (2003). Vanilloid receptor activation by 2- and 10-μm particles induces responses leading to apoptosis in human airway epithelial cells. Toxicol. Appl. Pharmacol. 192, 21-35.
2. 1 induces the transversion of G→T in codon 249 of the p53 tumor suppressor gene in human hepatocytes. Proc. Natl. Acad. Sci., U.S.A. 90, 8586-8590.
3. 1 and identification of the major aflatoxin B1- DNA adducts formed in cultured human bronchus and colon. Cancer Res. 39, 694-698.
4. 1 in mammalian airway epithelium. Carcinogenesis 12, 305-310.
5. 1 by mammalian pulmonary tissues. Toxicol. Lett. 75, 119-125.
6. Barton, C. M., Staddon, S. L., Hughes, C. M., Hall, P. A., O'Sullivan, C., Kloppel, G., Theis, B., Russell, R. C., Neoptolemos, J., Williamson, R. C., et al. (1991). Abnormalities of the p53 tumour suppressor gene in human pancreatic cancer [published erratum appears in Br. J. Cancer (1992) 65(3), 485]. Br. J. Cancer 64, 1076-1082.
7. Bondy, G. S., and Pestka, J. J. (2000). Immunomodulation by fungal toxins. J. Toxicol. Environ. Health B Crit. Rev. 3, 109-43.
8. Carnero, A., Hudson, J. D., Hannon, G. J., and Beach, D. H. (2000). Loss-of-function genetics in mammalian cells: The p53 tumor suppressor model. Nucleic Acids Res. 28, 2234-2241.
9. Cerutti, P., Hussain, P., Pourzand, C., and Aguilar, F. (1994). Mutagenesis of the H-ras protooncogene and the p53 tumor suppressor gene. Cancer Res. 54, 1934s-1938s.
10. Chang, F., Syrjanen, S., Tervahauta, A., and Syrjanen, K. (1993). Tumourigenesis associated with the p53 tumour suppressor gene. Br. J. Cancer 68, 653-661.
11. Chen, L., Marechal, V., Moreau, J., Levine, A. J., and Chen, J. (1997). Proteolytic cleavage of the mdm2 oncoprotein during apoptosis. J. Biol. Chem. 272, 22966-22973.
12. 1. Toxicol. Appl. Pharmacol. 109, 196-206.
13. 1 in rabbit lung and liver microsomes. Carcinogenesis 11, 823-827.
14. 1 biotransformation in rabbit pulmonary and hepatic microsomes. Toxicology 74, 19-32.
15. 1 in human lung. Carcinogenesis 17, 2487-2494.
16. Erhardt, J. A., Ohlstein, E. H., Toomey, J. R., Gabriel, M. A., Willette, R. N., Yue, T.-L., Barone, F. C., and Parsons, A. A. (2001). Activation of caspase-3/caspase-3-like activity in rat cardiomyocytes by an RGD peptide, but not the GPIIb/IIIa antagonist lotrafiban. Thromb. Res. 103, 143-148.
17. Freedman, D. A., Wu, L., and Levine, A. J. (1999). Functions of the MDM2 oncoprotein. Cell. Mol. Life Sci. 55, 96-107.
18. Gartenhaus, R. B., Wang, P., and Hoffmann, P. (1996). Induction of the WAF1/CIP1 protein and apoptosis in human T-cell leukemia virus type I-transformed lymphocytes after treatment with adriamycin by using a p53-independent pathway. Proc. Natl. Acad. Sci. U.S.A. 93, 265-268.
19. Gerwin, B. I., Spillare, E., Forrester, K., Lehman, T. A., Kispert, J., Welsh, J. A., Pfeifer, A. M., Lechner, J. F., Baker, S. J., Vogelstein, A., et al. (1992). Mutant p53 can induce tumorigenic conversion of human bronchial epithelial cells and reduce their responsiveness to a negative growth factor, transforming growth factor beta 1. Proc. Natl. Acad. Sci. U.S.A. 89, 2759-2763.
20. Hainaut, P., and Vahakangas, K. (1997). p53 as a sensor of carcinogenic exposures: Mechanisms of p53 protein induction and lessons from p53 gene mutations. Pathol. Biol. (Paris) 45, 833-844.
21. Hayes, R. B., van Nieuwenhuize, J. P., Raatgever, J. W., and Ten Kate, F. J. (1984). Aflatoxin exposures in the industrial setting: An epidemiological study of mortality. Food Chem. Toxicol. 22, 39-43.
22. He, Z., Ma, W. Y., Hashimoto, T., Bode, A. M., Yang, C. S., and Dong, Z. (2003). Induction of apoptosis by caffeine is mediated by the p53, Bax, and caspase 3 pathways. Cancer Res. 63, 4396-4401.
23. Hesketh, R. (1997). The Oncogene and Tumour Suppressor Gene Facts Book. Academic Press, San Diego. CA.
24. 1 exposure in hepatocellular carcinoma patients from Thailand. Int. J. Cancer 53, 51-55.
25. Hsieh, J. K., Kletsas, D., Clunn, G., Hughes, A. D., Schachter, M., and Demoliou-Mason, C. (2000). p53, p21(WAF1/CIP1), and MDM2 involvement in the proliferation and apoptosis in an in vitro model of conditionally immortalized human vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 20, 973-981.
26. Hsing, A., Faller, D. V., and Vaziri, C. (2000). DNA-damaging aryl hydrocarbons induce Mdm2 expression via p53- independent post-transcriptional mechanisms. J. Biol. Chem. 275, 26024-26031.
27. 1 by pulmonary, renal, and hepatic cytochrome P450s from rats. Mutat. Res. 269, 231-236.
28. Kastan, M. B., Zhan, Q., el-Deiry, W. S., Carrier, F., Jacks, T., Walsh, W. V., Plunkett, B. S., Vogelstein, B., and Furnace, A. J., Jr. (1992). A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia telangiectasia. Cell 71, 587-597.
29. Kato, T., Nakasa, H., Ohmori, S., Kamataki, T., Itahashi, K., Shimada, T., Rikihisa, T., and Kitada, M. (1994). Possible occurrence of P450 related to P450 HFLb in extrahepatic tissues of human fetuses and its contribution to metabolic activation of promutagens. Mutat. Res. 310, 73-77.
30. 1 activation in human lung. Toxicol. Appl. Pharmacol. 144, 88-95.
31. Kew, M. C. (1992). Tumours of the liver. Scand. J. Gastroenterol. Suppl. 192, 39-42.
32. 1. Toxicol. Appl. Pharmacol. 165, 45-52.
33. Lane, D. P. (1992). Cancer p53, guardian of the genome [news; comment] [see comments]. Nature 358, 15-16.
34. Lasky, T., and Magder, L. (1997). Hepatocellular carcinoma p53 G > T transversions at codon 249: The fingerprint of aflatoxin exposure? Environ. Health Perspect. 105, 392-397.
35. 1 induced p53 mutant 249 is caused by activation of transcription complexes; implications for a gain-of-function during the formation of hepatocellular carcinoma. Oncogene 19, 3717-3726.
36. Levresse, V., Moritz, S., Renier, A., Kheuang, L., Galateau-Salle, F., Mege, J. P., Piedbois, P., Salmons, B., Guenzburg, W., and Jaurand, M. C. (1998). Effect of simian virus large T antigen expression on cell cycle control and apoptosis in rat pleural mesothelial cells exposed to DNA damaging agents. Oncogene 16, 1041-1053.
37. 1 to DNA in guinea-pig tissue microsomes. Carcinogenesis 11, 1915-1919.
38. 1 by lipoxygenases, prostaglandin H synthase and cytochrome P450 monooxygenase in guinea-pig tissues. Carcinogenesis 13, 533-539.
39. 1 biotransformation in guinea pig tissues: Effects of beta-naphthoflavone treatment. Arch. Toxicol. 67, 379-385.
40. 1-induced DNA adduct formation and p53 mutations in CYP450-expressing human liver cell lines. Carcinogenesis 18, 1291-1297.
41. Mace, K., Bowman, E. D., Vautravers, P., Shields, P. G., Harris, C. C., and Pfeifer, A. M. (1998). Characterization of xenobiotic-metabolizing enzyme expression in human bronchial mucosa and peripheral lung tissues. Eur. J. Cancer 34, 914-920.
42. Mace, K., Gonzalez, F. J., McConnell, I. R., Garner, R. C., Avanti, O., Harris, C. C., and Pfeifer, A. M. (1994). Activation of promutagens in a human bronchial epithelial cell line stably expressing human cytochrome P450 1A2. Mol. Carcinog. 11, 65-73.
43. Maruyama, W., Youdim, M. B., and Naoi, M. (2001). Antiapoptotic properties of rasagiline, N-propargylamine-1(R)-aminoindan, and its optical (S)-isomer, TV1022. Ann. N.Y. Acad. Sci. 939, 320-329.
44. Matlashewski, G., Banks, L., Pim, D., and Crawford, L. (1986). Analysis of human p53 proteins and mRNA levels in normal and transformed cells. Eur. J. Biochem. 154, 665-672.
45. Maxwell, S. A. (1994). Selective compartmentalization of different mdm2 proteins within the nucleus. Anticancer Res. 14, 2541-2547.
46. May, P., and May, E. (1995). P53 and cancers. Pathol. Biol. (Paris) 43, 165-173.
47. Mendrysa, S. M., McElwee, M. K., and Perry, M. E. (2001). Characterization of the 5′ and 3′ untranslated regions in murine mdm2 mRNAs. Gene 264, 139-146.
48. Miyazawa, K., Mori, A., and Okudaira, H. (1998). Establishment and characterization of a novel human rheumatoid fibroblast-like synoviocyte line, MH7A, immortalized with SV40 T antigen. J. Biochem. (Tokyo) 124, 1153-1162.
49. Mosmann, T. (1983). Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J. Immunol. Methods 65, 55-63.
50. Nichols, W. K., Mehta, R., Skordos, K., Mace, K., Pfeifer, A. M., Carr, B. A., Minko, T., Burchiel, S. W., and Yost, G. S. (2003). 3-Methylindole-induced toxicity to human bronchial epithelial cell lines. Toxicol. Sci. 71, 229-236.
51. Nigro, J. M., Baker, S. J., Preisinger, A. C., Jessup, J. M., Hostetter, R., Cleary, K., Bigner, S. H., Davidson, N., Baylin, S., Devilee, P., et al. (1989). Mutations in the p53 gene occur in diverse human tumour types. Nature 342, 705-708.
52. Paajarvi, G., Viluksela, M., Pohjanvirta, R., Stenius, U., and Hogberg, J. (2005). TCDD activates Mdm2 and attenuates the p53 response to DNA damaging agents. Carcinogenesis 26, 201-208.
53. Perry, M. E., Mendrysa, S. M., Saucedo, L. J., Tannous, P., and Holubar, M. (2000). p76(MDM2) inhibits the ability of p90(MDM2) to destabilize p53. J. Biol. Chem. 275, 5733-5738.
54. Peterson, S. R., Gadbois, D. M., Bradbury, E. M., and Kraemer, P. M. (1995). Immortalization of human fibroblasts by SV40 large T antigen results in the reduction of cyclin D1 expression and subunit association with proliferating cell nuclear antigen and Waf1. Cancer Res. 55, 4651-4657.
55. Pochampally, R., Fodera, B., Chen, L., Lu, W., and Chen, J. (1999). Activation of an MDM2-specific caspase by p53 in the absence of apoptosis. J. Biol. Chem. 274, 15271-15277.
56. Pochampally, R., Fodera, B., Chen, L., Shao, W., Levine E. A., and Chen, J. (1998). A 60 kd MDM2 isoform is produced by caspase cleavage in non-apoptotic tumor cells. Oncogene 17, 2629-2636.
57. Porras, A., Gaillard, S., and Rundell, K. (1999). The simian virus 40 small-t and large-T antigens jointly regulate cell cycle reentry in human fibroblasts. J. Virol. 73, 3102-3107.
58. Ralhan, R., Sandhya, A., Meera, M., Bohdan, W., and Nootan, S. K. (2000). Induction of MDM2-P2 transcripts correlates with stabilized wild-type p53 in betel- and tobacco-related human oral cancer. Am. J. Pathol. 157, 587-596.
59. 1 by human liver microsomes: Role of cytochrome P450 IIIA enzymes. Toxicol. Appl. Pharmacol. 108, 436-447.
60. Reddel, R. R., Ke, Y., Gerwin, B. I., McMenamin, M. G., Lechner, J. F., Su, R. T., Brash, D. E., Park, J. B., Rhim, J. S., and Harris, C. C. (1988). Transformation of human bronchial epithelial cells by infection with SV40 or adenovirus-12 SV40 hybrid virus, or transfection via strontium phosphate coprecipitation with a plasmid containing SV40 early region genes. Cancer Res. 48, 1904-1909.
61. Saucedo, L. J., Myers, C. D., and Perry, M. E. (1999). Multiple murine double minute gene 2 (MDM2) proteins are induced by ultraviolet light. J. Biol. Chem. 274, 8161-8168.
62. Shimada, T., and Guengerich, F. P. (1989). Evidence for cytochrome P-450NF, the nifedipine oxidase, being the principal enzyme involved in the bioactivation of aflatoxins in human liver. Proc. Natl. Acad. Sci. U.S.A. 86, 462-465.
63. Soini, Y., Chia, S. C., Bennett, W. P., Groopman, J. D., Wang, J. S., DeBenedetti, V. M., Cawley, H., Welsh, J. A., Hansen, C., Bergasa, N. V., et al. (1996). An aflatoxin-associated mutational hotspot at codon 249 in the p53 tumor suppressor gene occurs in hepatocellular carcinomas from Mexico. Carcinogenesis 17, 1007-1012.
64. Stein, L. S., Stoica, G., Tilley, R., and Burghardt, R. C. (1991). Rat ovarian granulosa cell culture: A model system for the study of cell-cell communication during multistep transformation. Cancer Res. 51, 696-706.
65. Technau, A., Wolff, A., Sauder, C., Birkner, N., and Brandner, G. (2001). p53 in SV40-transformed DNA-damaged human cells binds to its cognate sequence but fails to transactivate target genes. Int. J. Oncol. 18, 281-286.
66. Thorburn, J., Frankel, A. E., and Thorburn, A. (2003). Apoptosis by leukemia cell-targeted diphtheria toxin occurs via receptor-independent activation of Fas-associated death domain protein. Clin Cancer Res. 9, 861-865.
67. 1 by normal human bronchial epithelial cells. J. Toxicol. Environ. Health A 63, 525-540.
68. 1 in cytochrome P450-expressing human lung cells. J. Toxicol. Environ. Health A 65, 853-867.
69. 1 activation and cytotoxicity in human bronchial cells expressing cytochromes P450 1A2 and 3A4. Cancer Res. 62, 105-112.
70. Villa, P. G., Henzel, W. J., Sensenbrenner, M., Henderson, C. E., and Pettmann, B. (1998). Calpain inhibitors, but not caspase inhibitors, prevent actin proteolysis and DNA fragmentation during apoptosis. J Cell Sci. 111, 713-722.
71. Wei, C., Caccavale, R. J., Kehoe, J. J., Thomas, P. E., and Iba, M. M. (2001). CYP1A2 is expressed along with CYP1A1 in the human lung. Cancer Lett. 171, 113-120.
72. Wolff, A., Technau, A., Ihling, C., Technau-Ihling, K., Erber, R., Bosch, F. X., and Brandner, G. (2001). Evidence that wild-type p53 in neuroblastoma cells is in a conformation refractory to integration into the transcriptional complex. Oncogene 20, 1307-1317.